Abvc Biopharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Lind Global Fund II LP, along with its general partner and managing member, disclosed a 3.2% beneficial ownership stake in ABVC BioPharma, Inc. as of June 30, 2025.
NASDAQ
Lind Global Fund II LP, along with its general partner Lind Global Partners II LLC and managing member Jeff Easton, has disclosed a passive beneficial ownership of 9.9% in ABVC BioPharma, Inc., totaling 1,325,000 shares.